Alembic Pharmaceuticals Limited has announced the incorporation of its wholly-owned subsidiary, Alembic Pharmaceuticals Global FZCO, in Dubai, United Arab Emirates. The incorporation date was August 24, 2026, and the company received this intimation on September 7, 2026. This strategic move aims to explore new business opportunities and promote, sell, and distribute the company’s pharmaceutical products in new markets. The subsidiary was established with a share capital of AED 100,000.
New International Subsidiary Established
Alembic Pharmaceuticals Limited has officially incorporated a new wholly-owned subsidiary named Alembic Pharmaceuticals Global FZCO. The incorporation took place in Dubai, United Arab Emirates, on August 24, 2026. This significant development was communicated to the parent company on September 7, 2026, aligning with the company’s growth strategy.
Strategic Objectives and Investment
The primary objective for establishing this subsidiary is to broaden the company’s business horizons by exploring new market opportunities. Furthermore, Alembic Pharmaceuticals Global FZCO is tasked with the critical functions of promoting, selling, and distributing Alembic Pharmaceuticals’ extensive range of pharmaceutical products internationally. The initial investment for the incorporation amounts to AED 100,000, with 100 shares of AED 1,000 each subscribed, representing 100% shareholding by Alembic Pharmaceuticals Limited.
Expansion into New Markets
This expansion into Dubai signifies a key step in Alembic Pharmaceuticals’ global outreach and commitment to making its healthcare solutions accessible in new regions. The company views this as a crucial initiative to enhance its market presence and revenue streams in the dynamic pharmaceutical sector.
Source: BSE
